Terazosin 2 mg and 5 mg tablets: Discontinued

Apotex advised that their brand of terozosin (Apo-Terozosin) 2 mg and 5 mg tablets were in short supply. Both presentations have been discontinued.

On this page

Updated 4 May 2021

All brands of terazosin will be delisted from the Schedule on 1 August 2021.

About this discontinuation

Apotex, the supplier of terazosin (Apo-Terazosin) 2 mg and 5 mg tablets, notified PHARMAC that they are unable to supply terazosin. The current stock of Apo-Terazosin in New Zealand:

  • 2 mg strength - exhausted
  • 5 mg strength - expected to be exhausted by mid-November.

PHARMAC has not been able to secure long-term supply of terazosin because terazosin is not used in significant volumes globally. 

Link Pharmaceuticals has sourced a very limited supply of an unregistered brand of terazosin, Teva Terazosin. This product is being distributed in New Zealand by Link Pharmaceuticals. Teva New Zealand Ltd is not involved in the supply or the distribution of this Teva Terazosin.

Teva Terazosin will be available in New Zealand by November 2020. 

What people taking terazosin need to know

Apo-Terazosin is no longer being supplied and there are limited supplies of an alternative brand of terazosin – Teva Terazosin - in New Zealand. If you are taking terazosin, you will need to talk to your prescriber about changing to an alternative treatment. 

Key dates for prescribers and pharmacists:

  • September 2020 –Apo-Terazosin 2 mg stock exhausted
  • 1 October 2020 – No new patients endorsement for terazosin in the Pharmaceutical Schedule
  • 1 October 2020 – Teva Terazosin (unapproved section 29) listed in the Pharmaceutical Schedule
  • November 2020 – Teva Terazosin (unapproved section 29) 2 mg, 5 mg stock available in New Zealand
  • Mid November 2020 – Current stock Apo-Terazosin 5 mg expected to run out
  • Late 2020 – Stock of Teva Terazosin is expected to run out
  • 1 August 2021 – Apo-Terazosin and Teva Terazosin delisted from the Pharmaceutical Schedule. 

What prescribers need to know

You will need to:

  • ensure no new patients are started on terazosin.
  • support your patients who are currently using terazosin to change to an alternative treatment as soon as possible.

There are suitable funded clinical alternatives available in New Zealand. Our clinical advisors recommend doxazosin as an alternative treatment. The supplier of funded doxazosin has advised they have sufficient stocks of doxazosin to meet increased demand. 

To help people transition to alternative products, we have sourced a very limited supply of Teva Terazosin. Teva Terazosin is an unapproved medicine in New Zealand. As such, it needs to be supplied in line with section 29 of the Medicines Act 1981. Prescribers need to be familiar with their obligations under section 29.

Only medical practitioners registered with the Medical Council of New Zealand can prescribe unapproved medicines. We appreciate that this limits the ability of non-medical prescribers to prescribe this medicine. We apologise for any inconvenience this causes.

Read more about section 29 prescribing on the Medsafe website(external link)

Information for your patients about unapproved medicines(external link)

What to tell your patients about Teva Terazosin:

  • Teva Terazosin tablets have the same active ingredient, at the same strength, as Apo-Terazosin tablets
  • Teva Terazosin has been approved for use in the UK
  • Teva Terazosin tablets (2 mg and 5 mg) will be:
    • listed in the Pharmaceutical Schedule from 1 October 2020
    • available for distribution November 2020
    • delisted from the Pharmaceutical Schedule mid-2021 once the stock is exhausted.

What pharmacists need to know

Terazosin can be dispensed to people who were taking it before 1 October 2020 and have their prescriptions endorsed accordingly. 

PHARMAC has been unable to source an alternative long-term supply of terazosin 2 mg and 5 mg tablets. To give people some time to transition to alternative products, we have sourced a very limited supply of Teva Terazosin. 

Link Pharmaceuticals is supplying Teva Terazosin. Teva New Zealand Limited is not involved in the distribution of this brand.

Chemical and presentation



Pack size 

Subsidy and price
(ex-man., ex. GST)

Terazosin tab 2 mg





Terazosin tab 5 mg 





Teva Terazosin is an unapproved medicine and will need to be supplied in accordance with section 29 of the Medicines Act. Wastage rules will apply.

We listed Teva Terazosin, 2 mg and 5 mg tablets on the Pharmaceutical Schedule on 1 October 2020 and it should be available in New Zealand in November. 

We had hoped to secure approximately six months demand of stock, however we have only been able to secure enough for one month’s supply at normal demand.

People using terazosin should therefore be advised to visit their prescriber to change to an alternative treatment.

Apo-Terazosin and Teva Terazosin will be delisted from the Pharmaceutical Schedule once we are confident supply has been exhausted.

Who to contact 

If you are a prescriber or pharmacist with questions about this supply issue, email enquiry@pharmac.govt.nz

If you have a question for the distributor, contact Link Pharmaceuticals(external link)

If you take terazosin, your doctor, nurse or pharmacist are the best people to answer your questions. PHARMAC cannot give clinical advice to anyone.